{"entity":{"id":"nct07368998","kind":"trial","name":"To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer","aka":["optINAVO"],"tldr":"A phase 2 trial of Inavolisib and Fulvestrant in advanced solid tumours, run by Hoffmann-La Roche, now recruiting.","summary":"To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer is a phase 2 interventional study registered as NCT07368998 by Hoffmann-La Roche, with 80 participants planned, started 2026-02-18 and due to reach its primary completion in 2028-10-31. Interventions recorded: Inavolisib and Fulvestrant.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07368998","url":"https://clinicaltrials.gov/study/NCT07368998"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["endocrine-therapy","kinase-inhibitors","pi3k-akt-mtor-inhibitors"],"targets":[],"drugs":["inavolisib","fulvestrant"],"companies":["flatiron-health"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07368998","phase":"2","setting":"A Phase II, Randomized, Open-Label Study Evaluating Two Inavolisib Dose Levels in Combination With Fulvestrant in Participants With PIK3CA-Mutated, HR-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer","sponsor":"Hoffmann-La Roche","started":"2026-02-18","startedType":"actual","enrolled":80,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07368998/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"},{"id":"pi3k-akt-mtor-inhibitors","kind":"technology","name":"PI3K, AKT and mTOR inhibitors","route":"/technologies/pi3k-akt-mtor-inhibitors/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/"},{"id":"inavolisib","kind":"drug","name":"Inavolisib","route":"/drugs/inavolisib/"}],"company":[{"id":"flatiron-health","kind":"company","name":"Flatiron Health (Roche)","route":"/companies/flatiron-health/"}]}}